BA
Bajaj Healthcare Ltd (BAJAJHCARE)
₹320.15
Mkt cap
₹1,083 Cr
P/E ratio
18.60
P/B
1.93
Div yield
0.47%
ROE
8.26%
ROCE
11.50%
EPS (TTM)
₹17.21
Book value
₹166
52W range
272–458
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations [1]
NSE BAJAJHCAREBSE 539872
Health check
Mixed
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBearish
52-week range
−30.10% from high₹320
₹272+17.55% from low₹458
Current
₹320.15
Prev close
₹318.50
Day
+0.52%
Price performance
1D
+0.44%
1W
−1.10%
1M
−1.46%
3M
−1.86%
6M
+5.07%
1Y
−28.47%
YTD
−23.52%
Financials
Revenue, profit & margin
P/E ratio
18.6×
BAJAJHCARE is 44% below the sector median of 33.4×
BAJAJHCARE18.6×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 101 | 109 | 134 | 132 | 133 | 123 | 154 | 149 | 148 | 161 | 153 | 166 | 176 | |
| YoY Sales growth | -48% | -18% | -13% | +2% | +32% | +13% | +15% | +13% | +11% | +31% | -1% | +11% | +19% | |
| Expenses | 82 | 89 | 118 | 108 | 109 | 101 | 143 | 124 | 121 | 131 | 130 | 137 | 145 | |
| Operating Profit | 19 | 20 | 16 | 24 | 25 | 22 | 12 | 25 | 27 | 31 | 23 | 29 | 31 | |
| OPM % | 19% | 18% | 12% | 19% | 18% | 18% | 8% | 16% | 18% | 19% | 15% | 17% | 18% | |
| Other Income | -7 | -7 | -36 | -0 | 4 | -1 | 13 | 1 | 0 | 1 | -34 | 1 | 1 | |
| Interest | 8 | 7 | 6 | 8 | 8 | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | |
| Depreciation | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 6 | 7 | 7 | 8 | 7 | 8 | |
| Profit before tax | -3 | -1 | -33 | 9 | 14 | 8 | 11 | 14 | 15 | 19 | -24 | 16 | 18 | |
| Tax % | 4% | 58% | -10% | 23% | 30% | -39% | 1% | 17% | 24% | 17% | -6% | 16% | 23% | |
| Net Profit | -3 | -2 | -30 | 7 | 9 | 12 | 11 | 12 | 11 | 16 | -23 | 14 | 14 | |
| EPS in Rs | -1.25 | -0.80 | -10.84 | 2.58 | 3.00 | 3.71 | 3.54 | 3.75 | 3.52 | 4.96 | -6.79 | 4.07 | 4.19 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202658.58%Promoter
Promoters58.58%0.01
FIIs2.09%0.10
DIIs1.96%0.04
Public37.36%0.06
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Bajaj Healthcare | ₹321.65 | 18.60 | 1,083 | 0.47% | 14 | +15.50% | 176 | +18.92% | 11.46% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts10
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 27 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 19 Oct - Audio recording of Q2 and H1 FY27 earnings call uploaded on company website.Announcement under Regulation 30 (LODR)-Newspaper Publication 19 OctAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 17 Oct - Bajaj Healthcare Q2 FY27 PAT rose 26.9% to Rs.14.1 crore; Cenobamate approval, GenRx acquisition approval reported.Compliances- Statement Of Deviation & Variation 17 Oct - Quarter ended September 30, 2026: no deviation in preferential issue warrant proceeds use.






